- Home
- GYRE vs RNP Comparison
GYRE vs RNP Comparison
Compare GYRE & RNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- RNP
- Stock Information
- Founded
- GYRE 2002
- RNP 2003
- Country
- GYRE United States
- RNP United States
- Employees
- GYRE N/A
- RNP N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- RNP Investment Managers
- Sector
- GYRE Health Care
- RNP Finance
- Exchange
- GYRE Nasdaq
- RNP Nasdaq
- Market Cap
- GYRE 897.1M
- RNP 1.1B
- IPO Year
- GYRE N/A
- RNP N/A
- Fundamental
- Price
- GYRE $7.71
- RNP $22.13
- Analyst Decision
- GYRE Strong Buy
- RNP
- Analyst Count
- GYRE 1
- RNP 0
- Target Price
- GYRE $18.00
- RNP N/A
- AVG Volume (30 Days)
- GYRE 86.3K
- RNP 117.6K
- Earning Date
- GYRE 08-11-2025
- RNP 01-01-0001
- Dividend Yield
- GYRE N/A
- RNP 7.94%
- EPS Growth
- GYRE N/A
- RNP N/A
- EPS
- GYRE 0.02
- RNP N/A
- Revenue
- GYRE $102,189,000.00
- RNP N/A
- Revenue This Year
- GYRE $21.04
- RNP N/A
- Revenue Next Year
- GYRE $89.64
- RNP N/A
- P/E Ratio
- GYRE $454.38
- RNP N/A
- Revenue Growth
- GYRE N/A
- RNP N/A
- 52 Week Low
- GYRE $6.11
- RNP $15.52
- 52 Week High
- GYRE $19.00
- RNP $21.27
- Technical
- Relative Strength Index (RSI)
- GYRE 49.56
- RNP 46.72
- Support Level
- GYRE $7.61
- RNP $22.22
- Resistance Level
- GYRE $8.40
- RNP $22.55
- Average True Range (ATR)
- GYRE 0.47
- RNP 0.24
- MACD
- GYRE 0.01
- RNP 0.03
- Stochastic Oscillator
- GYRE 34.29
- RNP 49.40
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.